Safety profile of antiviral medications: A pharmacovigilance study using the Italian spontaneous-reporting database

被引:10
|
作者
Pugi, Alessandra [1 ]
Bonaiuti, Roberto [1 ]
Maggini, Valentina [1 ]
Moschini, Martina [1 ]
Tucgori, Marco [1 ]
Leone, Roberto [1 ]
Rossi, Marco [1 ]
Motola, Domenico [1 ]
Piccinni, Carlo [1 ]
Ferrazin, Fernanda [1 ]
Sottosanti, Laura [1 ]
Mugelli, Alessandro [1 ]
Vannacci, Alfredo [1 ]
Lapi, Francesco [1 ]
机构
[1] Italian Med Agcy, Natl Pharmacovigilance Off, Pharmacovigilance Unit, Rome, Italy
关键词
CHRONIC HEPATITIS-C; ADVERSE DRUG-REACTIONS; ACUTE-RENAL-FAILURE; CASE/NON-CASE EVALUATION; ANTIRETROVIRAL THERAPY; CAUSALITY ASSESSMENT; RIBAVIRIN THERAPY; INTERFERON; ACYCLOVIR; NEUROTOXICITY;
D O I
10.2146/ajhp120665
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. The results of an analysis of suspected antiviral-associated adverse drug reactions (ADRs) in Italy over a 22-year period are presented. Methods. A case/non-case analysis was conducted using ADR reports compiled in the nationwide spontaneous-reporting database through September 2010. All reported events included in the analysis were evaluated and coded by drug safety experts; causality assessments were performed according to the algorithm of Naranjo et al. The association between an adverse reaction and antiviral use was assessed by estimating the reporting odds ratio (ROR), with 95% confidence interval (Cl), as a measure of disproportionality. Results. Overall, 863 reports of suspected ADRs involving antivirals and 42,430 reports of adverse reactions to other drugs were identified; of those events, 3.3% and 64.3% were determined to be definite or probable ADRs, respectively, and an additional 32.4% were deemed possibly drug related. Several ADRs were disproportionately associated with antivirals relative to other drugs: renal colic (ROR, 25.5; 95% CI, 13.3-49.0), lactic acidosis (ROR, 18.6; 95% Cl, 9.2-37.7), depression (ROR, 18.0; 95% CI, 11.6-27.9), anemia (ROR, 15.9; 95% CI, 12.3-20.4), hallucination (ROR, 4.3; 95% Cl, 2.7-7.1), neutropenia (ROR, 4.1; 95% Cl, 2.9-5.8), acute renal failure (ROR, 3.9; 95% Cl, 2.3-6.4), fever (ROR, 3.8; 95% Cl, 2.8-5.1), hyperpyrexia (ROR, 2.9; 95% Cl, 1.7-4.9), and asthenia (ROR, 1.8; 95% Cl, 1.2-2.8). Conclusion. Analysis of data from a large Italian database showed that, among antiviral agents, the ribavirin-interferon combination, acyclovir, valacyclovir, indinavir, and zidovudine accounted for the most serious hematologic, neuropsychiatric, and renal ADRs.
引用
收藏
页码:1039 / 1046
页数:8
相关论文
共 50 条
  • [21] Is it possible to identify risk factors for adverse drug reactions using a pharmacovigilance database based on spontaneous reporting?
    Noguchi, Yoshihiro
    Yoshimura, Tomoaki
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 (01)
  • [22] COVID-19-related pharmacovigilance surveillance based on a spontaneous reporting database
    Beyzarov, Elena
    Chen, Yan
    Caubel, Patrick
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 177 - 177
  • [23] Safety Profile of Intravitreal Anti-VEGF Drugs: An Analysis of the Italian Spontaneous Reporting System
    Marciano, Ilaria
    Cutroneo, Paola M.
    Giardina, Claudia
    Ientile, Valentina
    Potenza, Simona
    Sottosanti, Laura
    Ferrajolo, Carmen
    Trombetta, Costantino J.
    Trifiro, Gianluca
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 382 - 383
  • [24] Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study
    Iannone, Luigi Francesco
    Bennardo, Luigi
    Palleria, Caterina
    Roberti, Roberta
    De Sarro, Caterina
    Naturale, Maria Diana
    Dastoli, Stefano
    Donato, Luca
    Manti, Antonia
    Valenti, Giancarlo
    D'Amico, Domenico
    D'Attola, Santo
    De Francesco, Adele Emanuela
    Bosco, Vincenzo
    Di Paola, Eugenio Donato
    Nistico, Steven Paul
    Citraro, Rita
    Russo, Emilio
    De Sarro, Giovambattista
    PLOS ONE, 2020, 15 (11):
  • [25] Safety Profile of Antiviral Therapies for the Early Treatment/Prevention of COVID-19: Analysis of the International Pharmacovigilance Database VigiBase
    Bellitto, C.
    Ciccimarra, F.
    Arzenton, E.
    Luxi, N.
    Cutroneo, P. M.
    Poluzzi, E.
    Raschi, E.
    Moretti, U.
    Trifiro, G.
    DRUG SAFETY, 2022, 45 (10) : 1235 - 1235
  • [26] Ototoxic Adverse Drug Reactions: A Disproportionality Analysis Using the Italian Spontaneous Reporting Database
    Barbieri, Maria Antonietta
    Cicala, Giuseppe
    Cutroneo, Paola Maria
    Mocciaro, Eleonora
    Sottosanti, Laura
    Freni, Francesco
    Galletti, Francesco
    Arcoraci, Vincenzo
    Spina, Edoardo
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [27] The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
    Caruso, I.
    Di Gioia, L.
    Di Molfetta, S.
    Caporusso, M.
    Cignarelli, A.
    Sorice, G. P.
    Laviola, L.
    Giorgino, F.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2024, : 2671 - 2678
  • [28] Safety profile of adalimumab, etanercept and infliximab: analysis of disproportionalities in a Pharmacovigilance database
    Mendes, Diogo
    Alves, Carlos
    Batel-Marques, Francisco
    PHARMACOTHERAPY, 2014, 34 (06): : E109 - E109
  • [29] Differences in detected safety signals between benzodiazepines and non-benzodiazepine hypnotics: pharmacovigilance study using a spontaneous reporting system
    Toyoshima, Manabu
    Noguchi, Yoshihiro
    Otsubo, Manami
    Tachi, Tomoya
    Teramachi, Hitomi
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2021, 18 (05): : 1130 - 1136
  • [30] Consequences of security alerts on spontaneous reporting: Four analyses from the French pharmacovigilance database
    Gregoire, F.
    Pariente, A.
    Haramburu, F.
    Moore, N.
    DRUG SAFETY, 2006, 29 (10) : 934 - 934